XETRA - Delayed Quote EUR

Evotec SE (EVT.DE)

9.23

+0.07

(+0.82%)

At close: April 26 at 5:35 PM GMT+2

Evotec SE (NASDAQ:EVO) Q4 2023 Earnings Call Transcript

Evotec SE (NASDAQ:EVO) Q4 2023 Earnings Call Transcript April 24, 2024 Evotec SE misses on earnings expectations. Reported EPS is $-0.05 EPS, expectations were $-0.03333. Evotec SE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, welcome to […]

Insider Monkey 21 hours ago

EVT.DE
+0.82%
Evotec SE (ETR:EVT) Yearly Results: Here's What Analysts Are Forecasting For This Year

One of the biggest stories of last week was how Evotec SE ( ETR:EVT ) shares plunged 32% in the week since its latest...

Simply Wall St. yesterday

EVO

EVOTF
Evotec Full Year 2023 Earnings: EPS Misses Expectations

Evotec ( ETR:EVT ) Full Year 2023 Results Key Financial Results Revenue: €781.4m (up 4.0% from FY 2022). Net loss...

Simply Wall St. 2 days ago

EVO

EVOTF
Life Science-Focused Evotec Shares Plunge To 6 Year Lows On Gloomy Annual Forecast

European life science company Evotec SE (NASDAQ:EVO) announced a priority reset to optimize its business to meet evolving market demand and focus on profitable growth in 2024 and beyond. The company is focusing on and rightsizing organizations to overcome the challenging market environment and return to sustainable and profitable growth. Shared R&D and Just–Evotec Biologics will replace EVT Execute & EVT Innovate segments in a streamlined reporting structure as of Q1 2024. The priority reset is

Benzinga 2 days ago

EVT.DE
+0.82%
Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth

FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCE PRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 M EVOTEC’S REPORTING STRUCTURE WILL CHANGE ...

ACCESSWIRE 3 days ago

EVO

EVOTF
EQEvotec SE Appoints Dr Christian Wojczewski as Chief Executive Officer

HAMBURG, Germany - (NewMediaWire) - April 24, 2024 - The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer (...

NewMediaWire 3 days ago

EVO

EVOTF
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), ...

ACCESSWIRE 3 days ago

EVO

EVOTF
Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments

COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUND...

NewMediaWire 8 days ago

EVO

EVOTF
Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024

HAMBURG, Germany - (NewMediaWire) - April 17, 2024 - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024.The Company is going to hold a confe...

NewMediaWire 9 days ago

EVO

EVOTF
Evotec welcomes Aurélie Dalbiez as Chief People Officer

HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced the appointment of Aurélie Dalbiez as the Company's new Chief People Officer ("CPO"), effective ...

ACCESSWIRE 10 days ago

EVO

EVOTF
Health Care Roundup: Market Talk

AstraZeneca, Alpine Immune Sciences and more in the latest Market Talks covering the Health Care sector.

The Wall Street Journal 14 days ago

VRTX

EVO

EVOTF
Finding the Next Big Winners: 7 Stocks You Can Snag for Under $10

If you’re on the hunt for stocks under $10, look no further. The stock market has been off to a scorching start in 2024. Indexes have been going virtually straight up and momentum stocks are flying. With the economy remaining strong and the Federal Reserve potentially set to cut interest rates, this is seemingly a best of all worlds scenario for the equity market. The enthusiasm is understandable. But it does leave some investors wondering where the bargains are. After such a huge run in the maj

InvestorPlace last month

UAA

UMC

EVT.DE
+0.82%
Evotec (ETR:EVT shareholders incur further losses as stock declines 3.7% this week, taking three-year losses to 59%

Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of...

Simply Wall St. last month

EVT.DE
+0.82%
3 Stocks Set to Double: Your Fast Track to 2024 Gains

The stock market is soaring right now. It might seem too late to get in, given how far momentum stocks have already run up this year. However, there are still great opportunities if you know where to look. These are three quality stocks that have dropped sharply in recent months and are set for a big surge as things turn around. Looking for stocks set to double in 2024? Here are three to put on your watchlist today. Endava (DAVA) Source: BalkansCat / Shutterstock.comEndava (NYSE:DAVA) is one of

InvestorPlace last month

DAVA

EVT.DE
+0.82%
Evotec And Claris Ventures Streamline Access to Accelerate Programmes from Claris's Portfolio Companies into The Clinic

CLARIS'S PORTFOLIO COMPANIES RECEIVE EASY ACCESS TO EVOTEC'S FULL RANGE OF PRE-CLINICAL AND CLINICAL DEVELOPMENT AND MANUFACTURING CAPABILITIES AGREEMENT BUILDS ON SUCCESSFUL COLLABORATION BETWEEN EVOTEC AND CLARIS'S PORTFOLIO COMPANY IAMA HAMBURG, ...

ACCESSWIRE last month

EVO

EVOTF
7 Stable Stocks to Buy for 100% Returns by 2025

The seven stable stocks discussed below each have the potential to double by 2025 based on analyst target prices. Each of the seven stocks is also relatively stable based on the fact that none have a beta higher than 1.4. Most of the shares have a beta around 1 with several below that level. Beta measures volatility relative to the overall stock market with 1 meaning average volatility. All of the stocks listed below have a beta below 1.4 implying general stability. Most investors would characte

InvestorPlace last month

EXAS

DAR

EVT.DE
+0.82%
The Next Johnson & Johnson? 3 Healthcare Stocks That Investors Shouldn’t Ignore.

Johnson & Johnson (NYSE:JNJ) is one of the all-time great blue chip growth and income investments. JNJ stock has rallied approximately 7,000% over the past 40 years, and that figure doesn’t even factor in dividends. It is easily one of the best healthcare stocks on the market, but are there others that may take the throne? Long story short, investors that bought and held JNJ stock over the decades have enjoyed life-changing returns. While Johnson & Johnson continues to be a fine investment, it i

InvestorPlace 2 months ago

JNJ

CRL

EVT.DE
+0.82%
Just - Evotec Biologics Expands Development and Manufacturing Agreement with ABL for Broadly Neutralising Antibodies Against HIV

JUST - EVOTEC BIOLOGICS TO PROVIDE DEVELOPMENT AND PHASE I CLINICAL MANUFACTURING OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV AGREEMENT BUILDS ON PREVIOUS NIAID-FUNDED COLLABORATION TO DEVELOP A BROADLY NEUTRALISING ANTIBODY AGAINST HIV HAMBURG, ...

ACCESSWIRE 2 months ago

EVO

EVOTF
Evotec SE: Invitation to Conference Call

HAMBURG, Germany - (NewMediaWire) - January 22, 2024 - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) is going to hold a conference call to provide a statement as well as a business update on Monday, 22 Janua...

NewMediaWire 3 months ago

EVO

EVOTF
UPDATE 1-Evotec says it promptly reported share trades withheld by former CEO

German biotech firm Evotec on Monday said it had immediately reported trades in its shares by its former CEO as soon as it was informed of the transactions that he had kept under wraps for up to three years. "Evotec has acted always in compliance with the statutory regulations and our own very strict compliance code," supervisory board Chair Iris Loew Friedrich said in an analyst call. Evotec, which works in drug development with partners including Novo Nordisk, Bayer and Bristol-Myers Squibb, said on Jan. 3 that CEO Werner Lanthaler would resign for personal reasons after almost 15 years with the company.

Reuters 3 months ago

EVT.DE
+0.82%

Performance Overview

Return	EVT.DE	DAX PERFORMANCE-INDEX
YTD	-56.60%	+8.41%
1-Year	-44.62%	+14.42%
3-Year	-72.43%	+18.86%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Evotec SE (EVT.DE)

Evotec SE (NASDAQ:EVO) Q4 2023 Earnings Call Transcript

Evotec SE (ETR:EVT) Yearly Results: Here's What Analysts Are Forecasting For This Year

Evotec Full Year 2023 Earnings: EPS Misses Expectations

Life Science-Focused Evotec Shares Plunge To 6 Year Lows On Gloomy Annual Forecast

Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth

EQEvotec SE Appoints Dr Christian Wojczewski as Chief Executive Officer

Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments

Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024

Evotec welcomes Aurélie Dalbiez as Chief People Officer

Health Care Roundup: Market Talk

Finding the Next Big Winners: 7 Stocks You Can Snag for Under $10

Evotec (ETR:EVT shareholders incur further losses as stock declines 3.7% this week, taking three-year losses to 59%

3 Stocks Set to Double: Your Fast Track to 2024 Gains

Evotec And Claris Ventures Streamline Access to Accelerate Programmes from Claris's Portfolio Companies into The Clinic

7 Stable Stocks to Buy for 100% Returns by 2025

The Next Johnson & Johnson? 3 Healthcare Stocks That Investors Shouldn’t Ignore.

Just - Evotec Biologics Expands Development and Manufacturing Agreement with ABL for Broadly Neutralising Antibodies Against HIV

Evotec SE: Invitation to Conference Call

UPDATE 1-Evotec says it promptly reported share trades withheld by former CEO

Performance Overview